Cardiac anticoagulation therapy is a vital component in the comprehensive management of cardiovascular conditions, particularly those associated with the risk of blood clot formation. This specialized therapy aims to prevent the formation of clots within the heart's blood vessels, reducing the potential for serious complications such as strokes or heart attacks. Typically prescribed for individuals with atrial fibrillation, deep vein thrombosis, or mechanical heart valves, cardiac anticoagulation therapy involves the administration of medications like warfarin or direct oral anticoagulants. These medications work by interfering with the blood clotting process, ensuring a smoother flow of blood through the heart and vessels. While crucial for preventing thromboembolic events, the administration of cardiac anticoagulation therapy requires careful monitoring and individualized dosing to strike a delicate balance between preventing clots and minimizing the risk of bleeding complications. As advancements in medical research continue, ongoing refinements in cardiac anticoagulation therapies promise improved efficacy, reduced side effects, and better overall outcomes for individuals managing cardiovascular conditions.
Title : Frequency of residual risk in cardiovascular secondary prevention in patients treated at the Reina Fabiola University Clinic
Agustin Joison, Cordoba Catholic University, Argentina
Title : Revolutionizing heart health through Personalized & Precision Medicine (PPM): Towards personalized cardiovascular prevention, precision cardiac care & rehabilitation via optimizing Cardiac Hospital Networks
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Antibody-proteases as unique biomarkers, potential targets and translational tools of the next step generation to be used in personalized and precision cardiology practice
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Investigation of bergapten’s pharmacological activity against doxorubicin induced cardiotoxicity: supporting evidence from cellular and animal models
Bijoy Krishna Banik, National Institute of Pharmaceutical Education and Research (NIPER)-Guwahati, India